{"date":"2025-02-02","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-3176-2025-02-02-1601-b7ys7m","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2025-02-02","time":"16:01:49","subject":"開發中新藥OBP-301主持人發起之併用化放療治療食道癌第一期臨床試驗於美國ASCO研討會公布結果(更正安全性評估人數)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2025-02-02 16:01，「開發中新藥OBP-301主持人發起之併用化放療治療食道癌第一期臨床試驗於美國ASCO研討會公布結果(更正安全性評估人數)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}